Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. / Thomsen, K.; Christophersen, L.; Bjarnsholt, T.; Jensen, Peter Østrup; Moser, C.; Høiby, N.

In: Journal of Cystic Fibrosis, Vol. 15, No. 2, 03.2016, p. 171-178.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Thomsen, K, Christophersen, L, Bjarnsholt, T, Jensen, PØ, Moser, C & Høiby, N 2016, 'Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model', Journal of Cystic Fibrosis, vol. 15, no. 2, pp. 171-178. https://doi.org/10.1016/j.jcf.2015.08.002

APA

Thomsen, K., Christophersen, L., Bjarnsholt, T., Jensen, P. Ø., Moser, C., & Høiby, N. (2016). Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. Journal of Cystic Fibrosis, 15(2), 171-178. https://doi.org/10.1016/j.jcf.2015.08.002

Vancouver

Thomsen K, Christophersen L, Bjarnsholt T, Jensen PØ, Moser C, Høiby N. Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. Journal of Cystic Fibrosis. 2016 Mar;15(2):171-178. https://doi.org/10.1016/j.jcf.2015.08.002

Author

Thomsen, K. ; Christophersen, L. ; Bjarnsholt, T. ; Jensen, Peter Østrup ; Moser, C. ; Høiby, N. / Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. In: Journal of Cystic Fibrosis. 2016 ; Vol. 15, No. 2. pp. 171-178.

Bibtex

@article{3c0158a9ffb644f59457c883acf117e8,
title = "Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model",
abstract = "Background: Oral prophylactic therapy by gargling with pathogen-specific egg yolk immunoglobulins (IgY) may reduce the initial airway colonization with Pseudomonas aeruginosa in cystic fibrosis (CF) patients. IgY antibodies impart passive immunization and we investigated the effects of anti-P. aeruginosa IgY antibodies on bacterial eradication in a murine pneumonia model. Methods: P. aeruginosa pneumonia was established in Balb/c mice and the effects of prophylactic IgY administration on lung bacteriology, clinical parameters and subsequent inflammation were compared to controls. Results: Prophylactic administration of IgY antibodies targeting P. aeruginosa significantly reduced the bacterial burden by 2-log 24 h post-infection compared to controls and was accompanied by significantly reduced clinical symptom scores and successive inflammatory cytokine profile indicative of diminished lung inflammation. Conclusions: Passive immunization by anti-P. aeruginosa IgY therapy facilitates promptly bacterial clearance and moderates inflammation in P. aeruginosa lung infection and may serve as an adjunct to antibiotics in reducing early colonization.",
keywords = "Cystic fibrosis, IgY, Immunotherapy, Pseudomonas aeruginosa",
author = "K. Thomsen and L. Christophersen and T. Bjarnsholt and Jensen, {Peter {\O}strup} and C. Moser and N. H{\o}iby",
year = "2016",
month = mar,
doi = "10.1016/j.jcf.2015.08.002",
language = "English",
volume = "15",
pages = "171--178",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model

AU - Thomsen, K.

AU - Christophersen, L.

AU - Bjarnsholt, T.

AU - Jensen, Peter Østrup

AU - Moser, C.

AU - Høiby, N.

PY - 2016/3

Y1 - 2016/3

N2 - Background: Oral prophylactic therapy by gargling with pathogen-specific egg yolk immunoglobulins (IgY) may reduce the initial airway colonization with Pseudomonas aeruginosa in cystic fibrosis (CF) patients. IgY antibodies impart passive immunization and we investigated the effects of anti-P. aeruginosa IgY antibodies on bacterial eradication in a murine pneumonia model. Methods: P. aeruginosa pneumonia was established in Balb/c mice and the effects of prophylactic IgY administration on lung bacteriology, clinical parameters and subsequent inflammation were compared to controls. Results: Prophylactic administration of IgY antibodies targeting P. aeruginosa significantly reduced the bacterial burden by 2-log 24 h post-infection compared to controls and was accompanied by significantly reduced clinical symptom scores and successive inflammatory cytokine profile indicative of diminished lung inflammation. Conclusions: Passive immunization by anti-P. aeruginosa IgY therapy facilitates promptly bacterial clearance and moderates inflammation in P. aeruginosa lung infection and may serve as an adjunct to antibiotics in reducing early colonization.

AB - Background: Oral prophylactic therapy by gargling with pathogen-specific egg yolk immunoglobulins (IgY) may reduce the initial airway colonization with Pseudomonas aeruginosa in cystic fibrosis (CF) patients. IgY antibodies impart passive immunization and we investigated the effects of anti-P. aeruginosa IgY antibodies on bacterial eradication in a murine pneumonia model. Methods: P. aeruginosa pneumonia was established in Balb/c mice and the effects of prophylactic IgY administration on lung bacteriology, clinical parameters and subsequent inflammation were compared to controls. Results: Prophylactic administration of IgY antibodies targeting P. aeruginosa significantly reduced the bacterial burden by 2-log 24 h post-infection compared to controls and was accompanied by significantly reduced clinical symptom scores and successive inflammatory cytokine profile indicative of diminished lung inflammation. Conclusions: Passive immunization by anti-P. aeruginosa IgY therapy facilitates promptly bacterial clearance and moderates inflammation in P. aeruginosa lung infection and may serve as an adjunct to antibiotics in reducing early colonization.

KW - Cystic fibrosis

KW - IgY

KW - Immunotherapy

KW - Pseudomonas aeruginosa

U2 - 10.1016/j.jcf.2015.08.002

DO - 10.1016/j.jcf.2015.08.002

M3 - Journal article

C2 - 26303991

AN - SCOPUS:84939600789

VL - 15

SP - 171

EP - 178

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 2

ER -

ID: 168882053